Introduction {#S1}
============

Bone loss is one of the most common comorbidities of patients with rheumatoid arthritis (RA). Depending on the population studied, 10--56% of RA patients suffer from osteoporosis, and consequently RA patients are at an increased risk of low-trauma fractures as compared to the general population ([@B1], [@B2]).

In healthy individuals, bone homeostasis is maintained by a balance between bone formation and bone resorption ([@B3]). A link between inflammation and bone loss has been suggested for decades, and it was supported by *in vitro* observations and animal models showing enhanced bone resorption under the influence of pro-inflammatory cytokines including interleukin (IL)-1, IL-6, and TNF-α ([@B4]). T-cells are one of the most important promoters of osteoclastogenesis, and the first evidence for the capacity of T-cells to cause bone loss was provided by Kong et al. in 1999 by illustrating that T-cell-produced receptor activator of nuclear factor kappa-B ligand (RANKL) triggered osteoclastogenesis directly in a mouse model of adjuvant-induced arthritis ([@B5]). More recently, another study showed that T-cell-deficient mice were resistant to bone loss using a mouse model of postmenopausal osteoporosis ([@B6]). Subsequently, numerous other studies have investigated the potential role of T-cells to interfere with bone homeostasis ([@B7], [@B8]).

Premature immunosenescence including the accumulation of senescent CD4^+^ T-cells seems to be a hallmark feature of RA ([@B9], [@B10]). Senescent T-cells are characterized by the loss of CD28, eroded telomeres, the lower content of T-cell receptor excision circles, the expression of pro-inflammatory molecules, and the gain of effector functions ([@B11]--[@B13]). Notably, senescent CD28^−^ T-cell prevalence correlated with disease severity in RA ([@B9], [@B14]).

The role of immunosenescence in the context of osteoporosis, however, is elusive so far. The aim of this study was to investigate whether senescent CD4^+^28^-^ T-cells are associated with early bone loss in RA patients.

Materials and Methods {#S2}
=====================

Study Population {#S2-1}
----------------

This was a prospective study on 107 consecutive patients with RA meeting the 2010 ACR/EULAR criteria ([@B15]) and 113 consecutive individuals without RA (non-RA) referred for dual-energy X-ray absorptiometry (DXA) scan. These non-RA subjects were subsequently classified either "healthy" or having "primary osteoporosis/osteopenia" according to the WHO criteria (osteoporosis in case of *T*-score of less or equal to −2.5 and osteopenia if *T*-score was between −2.5 and −1.0) ([@B16]). Patients were recruited at the outpatient clinics of the Rheumatology and Endocrinology Departments of the Medical University Graz, respectively. Detailed family and medical history including disease duration, prior and current treatments, as well as fracture risk assessment tool (FRAX) ([@B17]) data identifying clinical risk factors for osteoporosis and osteoporotic fractures were obtained from each individual. Clinical visits of RA patients were performed at baseline and subsequently for every 6 months up to 2 years. Non-RA controls underwent a baseline visit only. Synovial fluid samples were obtained from RA patients undergoing routine joint aspiration.

This study was approved by the Institutional Review Board of the Medical University Graz, and written informed consent was obtained from each individual.

Bone Mineral Density {#S2-2}
--------------------

Measurement of BMD by DXA was performed according to routine protocols. All RA patients underwent the scans at baseline, after 1 year and after 2 years, whereas controls underwent baseline scans only. BMD was assessed at the lumbar spine (L1--L4) and the left (or the right, if not possible otherwise) hip and femoral neck. Vertebral bodies with significant degenerative changes or compressive fractures (as judged by the investigating physician) were excluded from analysis, and the mean BMD was calculated using the remaining vertebral bodies (applicable only in case of at least two adjacent analyzable vertebrae). BMD was expressed in g/cm^2^ and has a *T*-score, which is derived from the SD of bone-healthy comparators.

Laboratory Parameters and Parameters of Bone Metabolism {#S2-3}
-------------------------------------------------------

Laboratory parameters at baseline and every 6 months during follow-up were determined (detailed in Figure [S1](#SM1){ref-type="supplementary-material"} in Supplementary Material).

Peripheral Blood Mononuclear Cells (PBMCs) and Cell Culture {#S2-4}
-----------------------------------------------------------

Peripheral venous blood or synovial fluid was drawn from each individual, and PBMCs were isolated by Histopaque density-gradient centrifugation. The total cell number was determined by a Beckmann Coulter. Cells were cultured at 1 × 10^6^ cells/ml in RPMI 1640 containing 10% fetal calf serum, 2 mM [l]{.smallcaps}-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin in the presence of 20 U/ml human-recombinant IL-2 (SIGMA, Vienna, Austria) and initial stimulation with 10 μg/ml plate-bound anti-CD3 Ab (eBioscience).

For stimulation assays, PBMCs were stimulated with 100 ng/ml of IL-15, IL-6, and, TNF-α (all Sigma-Aldrich) for 3 days or with 10 μg/ml plate-bound anti-CD3 Ab overnight. Unstimulated cells were served as a negative control.

Flow Cytometry {#S2-5}
--------------

Surface and intracellular staining of freshly isolated PBMCs was performed according to routine protocols and using appropriate combinations of antibodies for the detection of CD3, CD4, CD8, CD28, CD45RA, CD45RO, CD57 (all Becton Dickinson, San Diego, CA, USA), and RANKL (eBioscience). For intracellular staining of cytokines and intracellular RANKL, Golgi transport was inhibited by Brefeldin A (10 ng/ml) and Monensin (10 ng/ml) for 4 h prior to intracellular staining. Appropriate isotype controls were used. Stained cells were measured using a FACS Canto II (Becton Dickinson), and data analysis was conducted with DIVA software and FlowJo.

Isolation of T-Cell Subsets {#S2-6}
---------------------------

For functional assays, CD4^+^ T-cells were isolated by the positive selection of PBMCs labeled with magnetic-bead-conjugated anti-human CD4 mAbs using MACS MultiSort Kit and autoMACSPro according to manufacturer's instructions (Miltenyi Biotech, Amsterdam, The Netherlands). Purified CD4^+^ T-cells were then separated into the CD28^+^ and CD28^−^ fractions by another sorting step using FACS technology (FACS Aria). For validation, flow cytometry was performed to determine the purity (\>95%) of selected cells.

Isolation of Monocytes and Osteoclast Differentiation {#S2-7}
-----------------------------------------------------

Separation of the monocyte fraction from PBMCs was carried out by the plastic adherence technique using 96-well plates (0.3 × 10^6^ cells/well) and serum-free α-MEM supplemented with 1% penicillin/streptomycin, 10 ng/ml M-CSF, and 1 ng/ml TGF-β (Peprotech, Hamburg, Germany). Monocytes were obtained from healthy donors. After 5--7 days, monocyte-enriched cells were washed with PBS and treated with trypsin/EDTA for detachment. Monocytes of 5 × 10^4^ were then cultivated for 13 days in the absence or presence of 1 × 10^5^ CD4^+^CD28^+^ and CD4^+^CD28^−^ T-cells from RA patients or 1 ng/ml RANKL (Peprotech) as a positive control. Medium was replaced twice weekly. Visual inspection confirmed the continued adherence of cells with each change of medium.

Osteoclast differentiation was evaluated by staining cells for tartrate-resistant acid phosphatase (TRAP) using the Leukocyte Acid Phosphatase Kit (Sigma-Aldrich, Vienna, Austria) according to the manufacturer's instructions. Differentiated osteoclasts were defined as TRAP positive and multinucleated cells with ≥3 nuclei.

Statistical Analysis {#S2-8}
--------------------

All statistical analyses were performed using the SPSS program, version 23 (Chicago, IL, USA). The Kolmogorov--Smirnov test was used to analyze the distribution of the variables. In case of a parametric distribution of continuous variables, data were reported as mean and SD, and we applied the two-sided Student's *t*-test (comparison of two groups) for comparisons. In case of a non-parametric distribution, the results were described as median and range, and we conducted the Mann--Whitney *U*- and the Kruskal--Wallis tests. Paired data were compared with the Wilcoxon test. Correlation between variables was evaluated by Spearman's rank correlation coefficient.

Results {#S3}
=======

Patients' Characteristics {#S3-1}
-------------------------

In total, 220 (107 RA and 113 non-RA) patients were included in the investigation. Clinical baseline characteristics are depicted in Table [1](#T1){ref-type="table"}. FRAX data, full laboratory parameters, and results of genetic testing for a predisposition of lactose intolerance are shown in Tables S1--S3 in Supplementary Material. In the RA cohort, 12 (12.5%), 39 (40.6), and 26 (27.1) out of the 96 patients with available SDAI values had high-, moderate-, and low-disease activity, respectively, and 19 (19.8) patients were in remission ([@B18]). Six (6%) RA patients had early disease (≤2 years of duration). Clinical characteristics of RA patients at follow-up visits are shown in Table S4 in Supplementary Material.

###### 

Patients' characteristics.

  --------------------------------------------------------------------------------------------------------------------------------------------
                                                                       Non-RA                                     RA               *p*-Value
  -------------------------------------------------------------------- ------------------------------------------ ---------------- -----------
  Number                                                               113                                        107              

  Age (years)[^a^](#tfn1){ref-type="table-fn"}                         61.3 (±10.5)                               62.6 (±11.5)     0.372

  Female, *n* (%)                                                      96 (85)                                    81 (75.7)        0.148

  Disease duration (years)[^b^](#tfn2){ref-type="table-fn"}            n.a.                                       12.3 (0--46)     

  Bone mineral density                                                 *n* = 111                                  *n* = 105        

  Normal, *n* (%)                                                      38 (34.2)                                  28 (26.7)        0.303

  Osteopenia, *n* (%)                                                  31 (27.9)                                  55 (52.4)        \<0.001

  Osteoporosis, *n* (%)                                                44 (39.6)                                  22 (21)          0.005

  DAS                                                                                                                              

   SDAI[^b^](#tfn2){ref-type="table-fn"}                               n.d.                                       12.1 (0--50.7)   

   DAS28[^b^](#tfn2){ref-type="table-fn"}                              n.d.                                       3.3 (0.3--7.1)   

  Laboratory data                                                                                                                  

   ESR (mm/1st h)[^b^](#tfn2){ref-type="table-fn"}                     n.d.                                       15 (1--66)       

   CRP (mg/l)[^b^](#tfn2){ref-type="table-fn"}                         n.d.                                       3.5 (0--52)      

  Current medication                                                                                                               

   Corticosteroids, *n* (%)                                            1 (0.9)[^c^](#tfn3){ref-type="table-fn"}   25 (23.4)        

  Biologicals, *n* (%)                                                                                                             

   Anti-TNFα                                                           0                                          27 (25.2)        

   Tocilizumab                                                         0                                          6 (5.6)          

   Abatacept                                                           0                                          13 (12.1)        

   Rituximab                                                           0                                          3 (2.8)          

  DMARDs, *n* (%)                                                                                                                  

   Methotraxate                                                        0                                          59 (55.1)        

   Leflunomide                                                         0                                          16 (15)          

   Sulfasalazine                                                       0                                          6 (5.5)          

   Other                                                               0                                          5 (4.7)          

  NSAIDs, *n* (%)                                                                                                                  

   Regularly                                                           0                                          13 (12.1)        

   On demand                                                           0                                          74 (69.2)        

  Osteoporosis treatment, n (%); n in normal/osteopenia/osteoporosis                                                               

  Bisphosphonates                                                      29 (25.7)\                                 18 (16.8)\       0.102
                                                                       2/10/17                                    2/8/8            

  Vitamin D                                                            47 (41.6)\                                 33 (30.8)\       0.048
                                                                       9/14/24                                    6/16/11          

  Calcium                                                              43 (38.1)\                                 47 (43.9)\       0.490
                                                                       2/13/28                                    8/24/15          

  Raloxifene                                                           2 (1.8)\                                   0                
                                                                       0/1/1                                                       

  Strontium ranelate                                                   2 (1.8)\                                   0                
                                                                       0/0/2                                                       

  Denosumab                                                            1 (0.9)\                                   0                
                                                                       0/0/1                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------

*^a^Mean (±SD)*.

*^b^Median (range)*.

*^c^Due to asthma*.

*CRP, C-reactive protein (0--5 mg/l); DAS28, Disease Activity Score 28; DMARD, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate (0--30 mm/h); *n*, number; n.a., not applicable; n.d., not determined; NSAID, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; sDAI, simplified disease activity index*.

No Changes of BMD in RA Patients Over Time {#S3-2}
------------------------------------------

Only minor changes of BMD could be observed in RA patients for 2 years in this study (for details, see Table [2](#T2){ref-type="table"}).

###### 

BMD of RA patients over time of clinical visits.

                                                                 Baseline (*n* = 96)   12 months (*n* = 60)   24 months (*n* = 54)
  -------------------------------------------------------------- --------------------- ---------------------- ----------------------
  BMD spine[^a^](#tfn4){ref-type="table-fn"} (gm/cm^2^)          1.047 (±0.173)        1.074 (±0.153)         1.084 (±0.168)
  BMD hip[^a^](#tfn4){ref-type="table-fn"} (gm/cm^2^)            0.913 (±0.156)        0.923 (±0.128)         0.911 (±0.123)
  BMD femoral neck[^a^](#tfn4){ref-type="table-fn"} (gm/cm^2^)   0.880 (±0.144)        0.883 (±0.122)         0.874 (±0.116)

*^a^Data are depicted as mean (±SD)*.

A progression of bone loss as indicated by a loss of 5% of BMD over time (24 months) was observed in 17 (15.9%) (lumbar spine 13/total hip 4/femoral neck 6) RA patients. These 17 patients did not significantly differ from patients with stable BMD concerning medication and FRAX scores and lymphocyte subsets (data not shown). Baseline disease activity parameters correlated weakly with progressive bone loss at the lumbar spine (corr~coeff~ with DAS28 = 0.319, *p* = 0.033; corr~coeff~ with SDAI = 0.319, *p* = 0.029). In addition, a correlation of baseline osteocalcin levels with osteoporosis progression of the femoral neck (corr~coeff~ = 0.410, *p* = 0.002) was observed.

Senescent T-Cells Accumulate in Patients with Reduced Bone Mass {#S3-3}
---------------------------------------------------------------

Rheumatoid arthritis is associated with premature senescence of T-lymphocytes ([@B11], [@B13]), and the accumulation of senescent CD4^+^CD28^−^ T-cells has been linked with disease severity ([@B9], [@B14]). The possible involvement of senescent T-cells in RA-associated and primary bone loss, however, has not been studied so far.

Rheumatoid arthritis patients with reduced bone mass showed elevated frequencies of CD4^+^CD28^−^ T-cells compared to patients with normal bone mass \[2.2% (0--41.2) vs. 0.5% (0.1--8.6), *p* = 0.013, Figure [1](#F1){ref-type="fig"}A\], whereas the prevalence of CD8^+^CD28^−^ T-cells was not different between the groups \[45.2% (3.4--89.3) vs. 37.4% (10--61), *p* = 0.197, Figure [1](#F1){ref-type="fig"}B\]. RA patients with osteoporosis showed the highest levels of senescent CD4^+^ T-cells \[4.4% (0.2--39.7)\] as compared to RA patients with osteopenia \[1.4% (0--41.2)\] and patients with normal bone mass \[0.5% (0.1--8.6), Figure [S1](#SM1){ref-type="supplementary-material"}A in Supplementary Material\].

![The accumulation of CD4^+^CD28^−^ T-cells in patients with reduced bone mineral density (BMD). Graphs show **(A)** representative dot plots of freshly isolated CD4^+^CD28^−^ T-cells in rheumatoid arthritis (RA) patients with normal and reduced BMD and CD4^+^CD28^−^ T-cell frequencies in RA and non-RA cohort; **(B)** frequencies of freshly isolated CD8^+^CD28^−^ T-cells in healthy individuals and patients with primary osteopenia/-porosis; **(C)** correlation of CD4^+^CD28^−^ T-cells of RA patients with *T*-score of the lumbar spine and **(D)** the hip; **(E)** frequencies of freshly isolated CD4^+^CD28^−^ T-cells; and **(F)** frequencies of CD8^+^CD28^−^ T-cells in synovial fluid of RA patients (yellow, *n* = 7) compared to peripheral blood (red). \**p* ≤ 0.05, **(A,B,E,F)** Mann--Whitney *U*-test, **(C,D)** Spearman's rank correlation.](fimmu-09-00095-g001){#F1}

In the non-RA cohort, we also noted increased frequencies of CD4^+^CD28^−^ T-cells \[2.9% (0.1--34) vs. 0.7% (0.1--7.3), *p* = 0.010, Figure [1](#F1){ref-type="fig"}A\] as well as CD8^+^CD28^−^ T-cells \[38.3% (4.1--82.1) vs. 28.7% (6.6--59.8), *p* = 0.035, Figure [1](#F1){ref-type="fig"}B\] in patients with reduced bone mass compared to healthy controls. Patients with osteopenia showed the highest levels of CD4^+^CD28^−^ T-cells \[3.7% (0.1--34)\] followed by patients with osteoporosis \[2.4% (0.1--19.2)\] and healthy controls \[0.7% (0.1--7.3), Figure [S1](#SM1){ref-type="supplementary-material"}B in Supplementary Material\].

In the RA cohort, frequencies of senescent CD4^+^CD28^−^ and CD8^+^CD28^−^ T-cells correlated significantly with BMD of the lumbar spine (CD4: corr~coeff~ = −0.361, *p* = 0.001, Figure [1](#F1){ref-type="fig"}C; CD8: corr~coeff~ = −0.248, *p* = 0.016), the hip (CD4: corr~coeff~ = −0.310, *p* = 0.003, Figure [1](#F1){ref-type="fig"}D; CD8: corr~coeff~ = −0.204, *p* = 0.045), and the femoral neck (CD4: corr~coeff~ = −0.275, *p* = 0.009; CD8: corr~coeff~ = −0.175, *p* = 0.088). Such correlations, however, were not observed in the non-RA group.

During follow-up, the frequencies of T-cell subsets remained stable in the RA cohort. None of the T-cell subsets at baseline predicted any change of BMD over time (data not shown).

To investigate the prevalence of CD4^+^CD28^−^ T-cells at the site of inflammation, we analyzed the samples of RA synovial fluid. The frequency of CD4^+^CD28^−^ T-cells was elevated compared to peripheral blood \[4.1% (1.7--24.3) vs. 1.4% (0--41.2), *p* = 0.047, Figure [1](#F1){ref-type="fig"}E\]. By contrast, the prevalence of CD8^+^CD28^−^ T-cells was diminished \[26.6% (15.4--34.5) vs. 43.1% (3.4--89.3), *p* = 0.013, Figure [1](#F1){ref-type="fig"}F\].

Elevated Surface RANKL Expression by Senescent T-Cells {#S3-4}
------------------------------------------------------

We next investigated whether senescent T-cells express RANKL, which is a key mediator of bone loss ([@B19]).

In the RA cohort, surface RANKL was significantly higher in CD4^+^CD28^−^ T-cells compared to CD28^+^ T-cells \[3.7% (0.2--57.9) vs. 2.4% (0.2--35.4), *p* = 0.001, Figure [2](#F2){ref-type="fig"}A\]. Within the CD28^+^ T-cell subset, memory CD45RO^+^ T-cells produced more surface RANKL than naïve CD45RA^+^CD4^+^ T-cells \[2.7% (0.2--38) vs. 2.2% (0.2--30.5), *p* \< 0.001, Figure [S2](#SM2){ref-type="supplementary-material"}A in Supplementary Material\]. In CD4^+^CD28^−^ T-cells isolated from synovial fluid, RANKL expression was comparable to that of CD4^+^CD28^−^ T-cells isolated from peripheral blood \[3.7% (0.2--57.9) vs. 2.8% (0.2--24.1), *p* = 0.893; Figure [2](#F2){ref-type="fig"}B\]. Intracellular production of RANKL was higher in CD4^+^CD28^−^ T-cells compared to that in CD4^+^CD28^+^ T-cells \[MFI: 901.5 (630--1069) vs. 660.5 (443--796), *p* = 0.028, Figure [2](#F2){ref-type="fig"}C\] in patients with RA. Within the CD4^+^CD28^+^ population, memory CD45RO^+^ T-cells produced more intracellular RANKL than naïve CD45RA^+^ T-cells \[781.5 (544--880) vs. 589.5 (373--669), *p* = 0.027, Figure [S2](#SM2){ref-type="supplementary-material"}C in Supplementary Material\].

![Increased receptor activator of nuclear factor kappa-B ligand (RANKL) expression by CD4^+^CD28^−^ T-cells. Graphs show **(A)** representative dot plots of freshly isolated RANKL^+^ cells as well as isotype control staining in CD4^+^CD28^+^ T-cells and frequencies of RANKL^+^ cells out of CD4^+^CD28^−^ (blue) and CD4^+^CD28^+^ (green) T-cells in RA (*n* = 107) and non-RA cohort (*n* = 113); **(B)** prevalences of freshly isolated RANKL^+^CD4^+^CD28^−^ T-cells in synovial fluid (yellow) compared to peripheral blood (red) and **(C)** a representative histogram as well as median fluorescence intensity (MFI) of intracellular RANKL in freshly isolated CD4^+^CD28^+^ T-cells (green) and senescent CD4^+^ T-cells (blue) of RA patients (*n* = 6). For all experiments, cells were analyzed directly *ex vivo*. \**p* ≤ 0.05 **(A--C)** Mann--Whitney *U*-test.](fimmu-09-00095-g002){#F2}

Results in the non-RA cohort were similar: surface RANKL production was significantly higher in CD4^+^CD28^−^ T-cells compared to that in CD28^+^ T-cells \[2.4% (0--32.1) vs. 1.3 (0--34.8), *p* = 0.023, Figure [2](#F2){ref-type="fig"}A\]. Again, memory CD4^+^ T-cells produced more surface RANKL than naïve CD4^+^ T-cells \[1.4% (0--30.8) vs. 1.2 (0--45.3), *p* \< 0.001, Figure [S2](#SM2){ref-type="supplementary-material"}B in Supplementary Material\].

Each T-cell subset (i.e., naïve, memory, and senescent) in the RA cohort expressed more surface RANKL compared to the respective subset in the non-RA group (naïve: *p* \< 0.001, memory: *p* = 0.001, senescent: *p* = 0.017).

IL-15 Promotes Upregulation of Surface RANKL Expression {#S3-5}
-------------------------------------------------------

TNF-α, IL-6, and IL-15 are cytokines that are strongly associated with the pathogenesis of RA and were also reported to promote osteoclastogenesis ([@B20]--[@B22]). We therefore tested the ability of these cytokines to alter RANKL expression in different T-cell subsets.

As depicted in Figure [3](#F3){ref-type="fig"}A, IL-15 significantly enhanced surface RANKL expression on both the CD28^+^ and the CD28^−^ CD4^+^ T-cell populations. The effect, however, was more prominent in CD28^−^ (5.4-fold higher expression compared to unstimulated cells) compared to CD28^+^ T-cells (3.5-fold). Within the CD28^+^ subset, IL-15 upregulated RANKL more strongly on memory (4.5-fold) compared to naïve T-cells (1.5-fold).

![Increased receptor activator of nuclear factor kappa-B ligand (RANKL) expression following stimulation with IL-15. Graphs show **(A)** representative dot plots as well as prevalences of RANKL^+^ cells in CD4^+^CD28^+^ T-cells (green) and senescent CD4^+^ T-cells (blue) following stimulation with 100 ng/ml IL-15 (*n* = 5), **(B)** 100 ng/ml IL-6 (*n* = 5) and **(C)** 100 ng/ml TNF-α (*n* = 5) for 3 days or with **(D)** 10 μg/ml anti-CD3 antibody (*n* = 8) overnight. Cells were isolated from rheumatoid arthritis patients. \**p* ≤ 0.05 **(A--D)**, Wilcoxon test.](fimmu-09-00095-g003){#F3}

TNF-α as well as IL-6 failed to alter RANKL expression in all T-cell subsets (Figures [3](#F3){ref-type="fig"}B,C). Stimulation with anti-CD3 led to an increase of surface RANKL expression on CD28^+^ T-cells (7.9-fold), whereas senescent T-cells remained almost unaffected (Figure [3](#F3){ref-type="fig"}D).

Intracellular production of RANKL was modestly enhanced by anti-CD3 in CD28^+^ (1.5-fold) and CD28^−^ T-cells (1.3-fold), whereas stimulation with IL-15 did not further enhance RANKL production on either cell subset.

Senescent T-Cells Effectively Induce Osteoclastogenesis {#S3-6}
-------------------------------------------------------

To evaluate whether the increased RANKL expression on CD28^−^ as compared to CD28^+^CD4^+^ T-cells results in a higher capacity to induce osteoclastogenesis *in vitro*, osteoclast differentiation assays were conducted. A higher number of TRAP + multinuclear cells and larger areas of bone resorbtion were observed in co-cultures of monocytes and senescent T-cells as compared to cultures involving CD28^+^ T-cells \[34 osteoclasts/well (12--51) vs. 23 (7--29), *p* = 0.046, Figure [4](#F4){ref-type="fig"} and Figure [S3](#SM3){ref-type="supplementary-material"} in Supplementary Material\]. Osteoclasts generated in the presence of either CD28^−^ or CD28^+^ T-cells were smaller and less intensively stained for TRAP than monocytes differentiated in cultures containing recombinant-soluble RANKL.

![Enhanced osteoclastogenesis in the presence of CD4^+^CD28^−^ T-cells. The graph shows the number of tartrate-resistant acid phosphatase (TRAP^+^) multinuclear cells per well of monocytes in the absence of soluble receptor activator of nuclear factor kappa-B ligand (sRANKL) \[negative control (NC), white\], in the presence of CD4^+^CD28^+^ T-cells (green) or CD4^+^CD28^−^ T-cells (blue), and monocytes in the presence of sRANKL \[positive control (PC), gray\]. Representative images are given, and TRAP^+^ multinuclear cells are indicated with yellow arrows. All T-cell subsets were isolated from rheumatoid arthritis patients. *n* = 7, \**p* ≤ 0.05, Mann--Whitney *U*-test.](fimmu-09-00095-g004){#F4}

Discussion {#S4}
==========

In the present work, we show that patients with systemic bone loss have a higher prevalence of circulating senescent CD4^+^CD28^−^ T-cells than individuals with normal BMD. RANKL is expressed at higher levels on senescent CD4^+^ T-cells compared to that on CD28^+^ T-cells, and its production can be stimulated with IL-15, a key cytokine in the pathogenesis of RA. Senescent CD4^+^ T-cells induce osteoclastogenesis more efficiently than CD28^+^ T-cells.

Several studies demonstrated that T-cells are involved in the bone-remodeling system and that RANKL-expressing T-cells promote local and systemic osteoporosis ([@B5], [@B6]). Besides, it has been demonstrated that senescent CD4^+^ T-cells were increased in patients with severe disease manifestations, and at the same time, these patients were at an increased risk of osteoporosis ([@B23]). These findings support our conclusion that senescent CD4^+^CD28^−^ T-cells play an important role in the promotion of osteoporosis in RA as well as in non-RA individuals. Interestingly, we observed similar frequencies of CD4^+^CD28^−^ T-cells in our RA and non-RA cohorts. Since our non-RA population contains an increased number of patients with reduced bone mass, this group is not comparable to healthy controls from other studies. Taken together, these findings lead to the conclusion that extra-articular and systemic manifestations are the main drivers of CD28^−^ T-cell emergence in RA and that bone loss and systemic inflammation might also increase the prevalence of these cell subsets in other populations ([@B24], [@B25]).

We observed that senescent CD4^+^ T-cells expressed higher levels of RANKL than CD28^+^ T-cells. In mouse models of aging, B-cells and bone marrow cells from aged mice also yielded higher RANKL levels as compared to young animals, suggesting that cells from the hematopoietic lineage gain RANKL expression along with cellular senescence ([@B26], [@B27]). Aged T-cells further acquire a senescence-associated secretory phenotype ("inflammaging"), leading to a pro-inflammatory milieu which favors bone loss ([@B10], [@B28]).

IL-15 is a key cytokine in the pathogenesis of RA. Elevated levels of IL-15 were found in RA synovium, and the concentrations of IL-15 in peripheral blood correlated strongly with disease activity ([@B29], [@B30]). Moreover, genetic variants in the IL-15 gene were reported to be associated with the progression of joint destruction in RA ([@B31]). In our study, IL-15 stimulation led to an increased RANKL expression in naïve, memory, and aged CD4^+^ as well as CD8^+^ T-cells. This up-regulation was most prominent in memory and aged compared to naïve lymphocytes. The pivotal role of IL-15 in promoting osteoclastogenesis is supported by a number of studies. Park et al., for example, reported that IL-15 up-regulates RANKL expression in rheumatoid synovial fibroblasts ([@B32]), and Okabe et al. showed, more recently, that IL-15 and RANKL act synergistically to induce osteoclastogenesis ([@B33]). Another study noted that mice lacking the IL-15 receptor have a higher BMD and a decreased number of osteoclasts. Interestingly, these mice showed an impairment of T-cell-dependent osteoclast activation and RANKL production ([@B20]).

Our study has some limitations: first, the capability of senescent CD4^+^ T-cells to induce osteoclastogenesis was not verified *in vivo*. Unfortunately, mouse models on CD4^+^CD28^−^ T-cells are not available so far, and therefore we have to rely on *in vitro* experiments as well as clinical studies to investigate the role of these cell subsets in rheumatic diseases. Nevertheless, we were able to show that these cells accumulate at sites of inflammation and retain a pro-osteoclastogenic phenotype. Second, we chose to include consecutive patients from our outpatients' clinic, and therefore the patient cohort is heterogeneous with various treatments including corticosteroids and therapeutics for osteoporosis. Third, the progression of bone loss was observed only in a minority of RA patients, resulting in a lack of power to investigate whether the baseline prevalence of senescent T-cells would have been a predictor of the progression of bone loss. Furthermore, we did not observe an association between senescent T-cells and parameters of bone metabolism.

Taken together, our study establishes a link between senescent T-cells and bone loss in humans. CD4^+^CD28^−^ T-cells accumulate in patients with reduced BMD and exhibit a pro-osteoclastogenic phenotype *in vitro* which is further enhanced by IL-15. This cell population might thus contribute to the pathogenesis of RA-associated and primary bone loss.
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###### 

The accumulation of CD4^+^CD28^−^ T-cells in patients with reduced bone mineral density (BMD). Graphs show **(A)** frequencies of freshly isolated CD4^+^CD28^−^ T-cells in patients with normal BMD, osteopenia, and osteoporosis in rheumatoid arthritis (RA) and non-RA cohort; **(B)** frequencies of freshly isolated CD8^+^CD28^−^ T-cells in patients with normal BMD, osteopenia, and osteoporosis in RA and non-RA cohort. \**p* ≤ 0.05, **(A,B)** Mann--Whitney *U*-test.
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Click here for additional data file.

###### 

Increased receptor activator of nuclear factor kappa-B ligand (RANKL) expression by CD4^+^CD28^−^ T-cells. Graphs show **(A)** prevalences of RANKL+ cells in freshly isolated naïve CD4^+^CD28^+^CD45RA^+^ T-cells (light green), memory CD4^+^CD28^+^CD45RO^+^ T-cells (dark green), and senescent CD4^+^CD28^−^ T-cells (blue) of rheumatoid arthritis (RA) patients and **(B)** the non-RA cohort; **(C)** median fluorescence intensity (MFI) of intracellular RANKL in freshly isolated naïve CD4^+^CD28^+^CD45RA^+^ T-cells (light green), memory CD4^+^CD28^+^CD45RO^+^ T-cells (dark green), and senescent CD4^+^CD28^−^ T-cells (blue) of RA patients. For all experiments, cells were analyzed directly ex vivo. \**p* ≤ 0.05, **(A--C)** Mann--Whitney *U*-test.
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###### 

Increased bone resorption of CD4^+^CD28^−^ T-cells. Representative microscopic images of bone resorption plates. We cultured 1.5 X 10^5^ monocytes in DMEM with 20 ng/mL M-CSF and 10 ng/mL TGF-β without T cells **(A)**, or 3 X 10^5^ CD^4+^CD28^+^ **(B)**, or 3 X 10^5^ CD^4+^CD28^−^ T-cells **(C)**, in bone resorption assay plates (Cosmo Bio) in the presence of 10 ng/ml sRANKL for 14 days. Monocytes stimulated with 30 ng/ml sRANKL served as a positive control **(D)**. Black indicates areas of resorption.
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